AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01928901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Bronchipret
Study NCT01928901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: administration of Bronchipret
Study NCT01928901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Sinupret Placebo
Study NCT01928901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: administration of Sinupret Placebo
Study NCT01928901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Bronchipret Placebo
Study NCT01928901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: administration of Bronchipret Placebo
Study NCT02013297 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT treatment
Description: For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy.
Study NCT02413827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of varlilumab and ipilimumab
Description: Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg.
Study NCT04521985 — intervention group
Intervention type: PROCEDURE
Intervention: thoracolumbar kyphosis surgery
Description: patients receiving surgery or not
Study NCT03783299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard RDT and HS-RDT
Description: All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
Study NCT03783299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard RDT and HS-RDT
Description: All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
Study NCT03783299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
Study NCT03783299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Phosphate
Description: If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
Study NCT00730080 — intervention group
Intervention type: DRUG
Intervention: Sapropterin (Kuvan)
Description: 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Study NCT01009606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual strategy
Description: Usual strategy
Study NCT01009606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified strategy
Description: Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
Study NCT00546000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.05% lotion
Description: Daily applications
Study NCT01267305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: 2.5mg IH qd(8AM) after operation
Study NCT01267305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin Calcium
Description: 4100AxaIU IH qd(8AM) after operation
Study NCT01267305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium
Description: 4100AxaIU IH q12h(8Am,8Pm) after operation
Study NCT01128244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Subjects will receive vitamin B6 supplementation.
Study NCT01128244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of labeled serine, methionine and leucine
Description: Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
Study NCT02611843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Supported Web CBT
Study NCT02611843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Managed Web CBT
Study NCT03454607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FREE robot
Description: FREE robot to hold endoscope
Study NCT04472455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HRME
Study NCT00858208 — intervention group
Intervention type: DRUG
Intervention: pegaptanib sodium
Description: pegaptanib sodium intravitreal injection every 6 weeks for 2 years
Study NCT02444052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Puros Cancellous Allograft
Description: Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
Study NCT02444052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobel Biocare Creos Cancellous Allograft
Description: Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
Study NCT04276519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen
Description: Opening of the mechanical interface of the nerve root, neurodynamics
Study NCT04276519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen
Description: Opening of the mechanical interface of the nerve root, neurodynamics
Study NCT02413827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC
Description: Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC.
Study NCT01919658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
Study NCT01467232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting
Description: Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
Study NCT01467232 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting
Description: Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
Study NCT03577431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: arTreg-CSB
Description: Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. If a minimum arTreg-CSB dose of 1 to \< 2.5 x 10\^6 cells, the product will be infused. If the dose obtained after product manufacture is \< 1 x 10\^6 cells, the product will not be infused. When the dose obtained after product manufacture is > 125 x 10\^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10\^6 cells, and ≥ 2.5 to 125 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes.
Study NCT03577431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion.
Study NCT03577431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
Study NCT03577431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
Study NCT03577431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol.
Study NCT02182375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA
Study NCT02182375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Study NCT01679275 — intervention group
Intervention type: OTHER
Intervention: measuring cerebral oxygenation
Study NCT03995381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aids
Description: Shared decision making with decision aids
Study NCT04333810 — intervention group
Intervention type: DEVICE
Intervention: Whoop strap 3.0
Description: WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
Study NCT01474642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine/Cisplatin(XP)
Description: Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
Study NCT01474642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine/Paditaxel(XG)
Description: Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
Study NCT00664716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 1
Description: experimental - one dose level
Study NCT00664716 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT00664716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 2
Description: experimental - second dose level
Study NCT00664716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 3
Description: experimental - third dose level
Study NCT00664716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 4
Description: experimental - fourth dose level
Study NCT00664716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 5
Description: experimental - fifth dose level
Study NCT00969787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: tablets, oral administration, single and multiple administrations
Study NCT02279186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Intravenous Injection
Study NCT04156815 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 1,565nm NAFL
Description: 1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
Study NCT04156815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1,565nm NAFL
Description: 1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
Study NCT00635752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
Study NCT00635752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Participants will receive regular therapy as is usually practiced in clinics
Study NCT02697136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Recombinant human apoA-I/phospholipid complexes
Study NCT02697136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP
Study NCT03770156 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Overall Impression of the current state and evolution since the attacks
Study NCT00101387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar PENS + General Conditioning and Aerobic Exercise
Description: As above
Study NCT00101387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar PENS
Description: As above
Study NCT00101387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Lumbar PENS
Description: Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
Study NCT00101387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control PENS + exercise
Description: as above
Study NCT02327806 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: pulsed electromagnetic field therapy
Study NCT04389086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.~If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI.
Study NCT00891228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
Study NCT04389086 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy.
Study NCT04389086 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy.
Study NCT04389086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery locally recurrent rectal cancer
Description: Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional.
Study NCT04389086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery locally recurrent rectal cancer
Description: Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional.
Study NCT03037736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
Study NCT03037736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
Study NCT03037736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be used as the placebo.
Study NCT03602053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC®
Description: 0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
Study NCT03602053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC 5D
Description: 0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
Study NCT03602053 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix®
Description: 1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
Study NCT00891228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
Study NCT00891228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone®
Description: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
Study NCT01880359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01880359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Study NCT01880359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT01880359 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy